Merck’s lipid-lowering pill is on track to become the first oral PCSK9 inhibitor to reach the market, after positive data from two pivotal trials were

Pfizer has won the battle for obesity drug developer Metsera, after rival Novo Nordisk said that it would not increase its bid above $10bn.

Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have

Welcome back to another edition of Endpoints Weekly! Fall is in full swing here in New York, with chilly temperatures and multicolored trees settling in.

Pfizer has won the bidding war for the obesity drug developer Metsera. The biotech accepted an increased bid from the New York pharma worth a